Neurotech's NTI164 Cannabinoid Therapy Shows Promise in Pediatric Neurological Disorders with Positive Phase II/III Data
核心洞察
Neurotech International (搜索)'s NTI164, a broad-spectrum oral cannabinoid therapy, met all primary and key secondary endpoints in its Phase II/III Harmony Study for Autism Spectrum Disorder (搜索), showing statistically significant improvements in anxiety, depression, and mood.
The company's first-in-human pharmacokinetic study confirmed NTI164 is rapidly absorbed with sustained plasma concentrations and excellent tolerability, supporting its suitability for long-term pediatric use.
NTI164 received orphan drug designation from both the FDA and European Commission for Rett Syndrome (搜索), with the Australian TGA determining eligibility for provisional designation to enable earlier patient access.
Neurotech International (搜索) has achieved significant clinical milestones with its proprietary cannabinoid therapy NTI164, demonstrating efficacy across multiple pediatric neurological disorders while advancing toward regulatory approval in key markets.
Clinical Success Across Multiple Indications
The company's flagship therapy, NTI164, a broad-spectrum oral cannabinoid, continued to show promise across several clinical programs. In Autism Spectrum Disorder (搜索), Neurotech's Phase II/III Harmony Study met all primary and key secondary endpoints, including statistically significant improvements in anxiety, depression, and mood. Extension data reaffirmed NTI164's excellent safety and sustained clinical benefit, with some patients now receiving more than three years of continuous treatment.
In Rett Syndrome (搜索), NTI164 has also delivered encouraging outcomes. Data from Phase I/II and extension studies showed functional improvements across multiple domains, with no serious adverse events reported. The therapy has gained significant regulatory recognition, receiving orphan drug designation from both the FDA and the European Commission. In Australia, the Therapeutic Goods Administration determined that NTI164 is eligible for provisional designation, potentially enabling earlier patient access.
Pharmacokinetic Study Validates Drug Profile
Neurotech announced positive results from its first-in-human pharmacokinetic study, which was conducted in healthy adult volunteers to evaluate the absorption, cannabinoid ratios, and systemic exposure profile of NTI164. The study was conducted in two parts: Part A assessed single-dose pharmacokinetics in four participants who received 20mg/kg/day of NTI164, administered in two divided doses over a single day, while Part B examined repeat-dose pharmacokinetics and sex-based dose-exposure dynamics in eight participants dosed twice daily over seven consecutive days.
The findings confirmed that NTI164 is rapidly absorbed, maintains sustained plasma concentrations, and demonstrates predictable dosing with excellent tolerability. Management said this outcome derisks late-stage clinical development and supports the drug's suitability for long-term use in pediatric settings. Consistent with previous preclinical GLP-compliant toxicology studies in rats and dogs, NTI164 displayed excellent tolerability with no systemic or organ-specific toxicities or serious adverse events.
CBDA Mechanism of Action Validated
The positive results, along with a recent independent study from Johns Hopkins University, support Neurotech's view that CBDA and other cannabinoids work as active therapies, not just as precursors to CBD. The company states that CBDA acts directly on the body, particularly by targeting inflammation in the brain.
Work in PANDAS/PANS (搜索) added further validation, with genomic and proteomic analyses showing NTI164 could reverse immune dysregulation in affected children, consistent with its proposed mechanism of action. While the FDA deferred a decision on orphan designation for this indication, it accepted Neurotech's scientific rationale, and the company will continue development while assembling further supporting data.
Strategic Leadership and Manufacturing Partnerships
Corporate renewal defined the year with the appointment of Dr. Anthony Filippis as Managing Director and CEO in February 2025. With more than 25 years' experience in sector leadership, partnering, and capital markets, Dr. Filippis brings the commercial acumen required to steer the company into its next growth phase. "We now have the clinical data, regulatory momentum, and leadership to deliver NTI164 to patients globally," Chairman Mark Davies said.
To ensure manufacturing scale-up and quality, Neurotech signed a development agreement with RH Pharma (搜索), a subsidiary of European Cannabis Company (搜索), to produce NTI164 to global pharmaceutical standards. The company also deepened its clinical expertise with the appointment of Dr. Bonni Goldstein, a leading US authority on cannabinoid medicine, as Chief Medical Advisor.
Financial Position and Regulatory Strategy
Neurotech reported a net loss of $10.6 million for the financial year 2025, compared to $5.1 million the prior year, with research and development costs accounting for nearly $10 million. Revenue fell to $2.6 million, primarily due to lower R&D grant income. Year-end cash reserves stood at $3 million. The board acknowledged the need for additional capital to support operations but said it remains confident in the company's ability to raise funds and advance its clinical and regulatory agenda.
Looking ahead, Neurotech's strategy centers on a dual regulatory pathway in Australia and the US. In Australia, the company is exploring expedited approval options with the TGA, while in the US, preparations are underway for an Investigational New Drug application to the FDA, scheduled for the 2026 financial year. The company also intends to deepen engagement with potential partners to support commercialization.
"The results of our first-in-human PK study represent another important clinical milestone for NTI164. The clear validation of systemic stability, safety and targeted therapeutic action highlights NTI164's potential as a disease-modifying therapy," said Dr. Filippis. "We are eager to advance NTI164 rapidly into the next stages of its development and regulatory progress, while actively pursuing commercial opportunities."